- About UCB US
- R & D
- Contact Us
UCB differentiates itself by combining the global infrastructure and expertise of a traditional pharmaceutical company with the speed, innovation and entrepreneurship of a biotech company.
The entrance to UCB headquarters in Smyrna, a suburb of Atlanta.
At UCB, patients are at the heart of everything we do. Since UCB was established in the U.S. in 1994, the U.S. affiliate of UCB has continuously maintained invaluable programs for patients, healthcare professionals, caregivers and patient communities. Many of the programs we support are noted for their innovative and pioneering work in healthcare.
UCB was established in the U.S. in 1994 through the acquisition of Whitby Pharmaceuticals and Northampton Medical. UCB acquired Celltech in June 2004, and acquired majority shares of Schwarz Pharma AG in December 2006, enriching UCB product development and pipeline and making it the world's fifth-largest biopharma company. The first UCB biologic product was commercially available soon thereafter in the U.S. UCB in the U.S. has two sites – a U.S. corporate headquarters in Atlanta, Georgia and clinical development in our Research Triangle Park offices in North Carolina.